Current Headlines

  1. Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, And Envol Biomedical Unite To Form The LNP Alliance--Accelerating Lipid Nanoparticle Drug Development 5/8/2025

    In a groundbreaking collaboration, Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services (NIS), and Envol Biomedical have joined forces to establish the LNP Alliance, a strategic partnership dedicated to advancing lipid nanoparticle (LNP) technology and accelerating the development of next-generation therapeutics.

  2. Cadence Unveils Millennium M2000 Supercomputer With NVIDIA Blackwell Systems To Transform AI-Driven Silicon, Systems And Drug Design 5/7/2025

    At its annual flagship user event, CadenceLIVE Silicon Valley 2025, Cadence today announced a major expansion of its Cadence Millennium Enterprise Platform with the introduction of the new Millennium M2000 Supercomputer featuring NVIDIA Blackwell systems, which delivers AI-accelerated simulation at unprecedented speed and scale across engineering and drug design workloads.

  3. Citizen Health Partner To Support Drug Development And Long-Term Patient Outcomes In PKP2 Cardiomyopathy 5/7/2025

    Citizen Health today announced a strategic partnership to support Rocket Pharmaceutical Inc.'s (Rocket Pharma) clinical and long-term data initiatives for arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene.

  4. Adcentrx Therapeutics Granted Fast Track Designation For ADRX-0706 Nectin-4 ADC For The Treatment Of Advanced Cervical Cancer 5/6/2025

    Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program, ADRX-0706, for the treatment of patients with locally advanced or metastatic squamous cell cervical cancer.

  5. Lundbeck Joins Forces With Danish Centre For AI Innovation To Improve Brain Health By Advancing Drug Discovery With Gefion AI Supercomputer 5/6/2025

    H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate Gefion, Denmark's flagship AI supercomputer. Lundbeck is one of the first pharmaceutical companies to leverage Gefion to accelerate drug discovery and development in neurological and psychiatric disorders.

  6. Accelerating Drug Discovery With A Single Carbon Atom 5/6/2025

    A research team from the University of Oklahoma has pioneered a groundbreaking method that could accelerate drug discovery and reduce pharmaceutical development costs. Their work, published in the Journal of the American Chemical Society, introduces a safe, sustainable way to insert a single carbon atom into drug molecules at room temperature.

  7. Formosa Pharmaceuticals And Almac Discovery Announce Licensing Agreement For ALM-401, A First-In-Class Bispecific ADC Targeting EGFR/ROR1 For The Treatment Of Solid Tumors 5/6/2025

    Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, for exclusive rights to the commercialization of ALM-401, a first-in-class, bispecific antibody drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.

  8. AGC Biologics Partners With Novelty Nobility For Cell Line Development And Phase I Preparations Of Antibody Drug Candidate 5/5/2025

    AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea.

  9. Lantern Advances Drug Candidate LP-184 With IND Clearance For Phase 1b/2 Clinical Trial In Triple Negative Breast Cancer (TNBC) 5/5/2025

    Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer.

  10. Iambic Announces Enchant v2, Its Next Generation AI Model For Predicting The Clinical Viability Of Drug Discovery Programs 5/5/2025

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, published on major advances to Enchant, Iambic’s breakthrough multimodal transformer model for predicting clinical and preclinical endpoints related to the drug discovery and development process.